Unmet needs in the management of schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 97-110

  Torres González, Francisco ^a   Ibanez Casas, Inmaculada ^a   Saldivia, Sandra ^a,b   Ballester, Dinarte ^a,c   Grandón, Pamela ^a,b   Moreno Küstner, Berta ^a,d   Xavier, Miguel ^a,e   Gómez Beneyto, Manuel ^a,f  

^a UNIVERSITY OF GRANADA   (Spain)

^b UNIVERSITY OF CONCEPCIÓN   (Chile)

^c UNIVERSIDADE DO VALE DO RIO DOS SINOS   (Brazil)

^d UNIVERSITY OF MÁLAGA   (Spain)

^e NOVA MEDICAL SCHOOL   (Portugal)

^f UNIVERSITY OF VALENCIA   (Spain)

Author keywords

Needs; Schizophrenia; Severe mental disorders; Unmet needs

Indexed keywords

NEUROLEPTIC AGENT; PLACEBO;

ANXIETY; CLINICAL STAGING MODEL; COMMUNITY CARE; COMORBIDITY; DEPRESSION; DISEASE ASSOCIATION; DISEASE MODEL; ECONOMIC ASPECT; EVIDENCE BASED PRACTICE; FOLLOW UP; HUMAN; HUMAN RIGHTS; INTERPERSONAL COMMUNICATION; MENTAL HEALTH SERVICE; OBSESSIVE COMPULSIVE DISORDER; PANIC; PATIENT MONITORING; POSTTRAUMATIC STRESS DISORDER; PSYCHOSOCIAL CARE; QUALITY OF LIFE; REVIEW; SCHIZOPHRENIA; SELF HELP; SOMATOFORM DISORDER; SUBSTANCE ABUSE;

EID: 84892554562     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S41063     Document Type: Review

References (153)

1. Gilbody SM, House AO, Sheldon TA. Outcome measures and needs assessment tools for schizophrenia and related disorders. Cochrane Database Syst Rev. 2003;(1):CD003081.
2. Phelan M, Slade M, Thornicroft G, etal. The Camberwell Assessment of Need: the validity and reliability of an instrument to assess the needs of people with severe mental illness. Br J Psychiatry. 1995;167(5):589-595.
3. Saldivia S, Torres-González F, Runte-Geidel A, etal. Standardization of the MARISTAN scale to measure needs in people with schizophrenia and related psychoses. Int J Soc Psychiatry. Epub April 10, 2013.
4. Torres-Gonzalez F, Runte-Geidel A, Antonioli C, etal. Standardised measures of needs, stigma and informal care in schizophrenia using a bottom-up, cross-cultural approach. Ment Health Fam Med. 2012; 9(2):125-134.
5. Joska J, Flisher AJ. The assessment of need for mental health services. Soc Psychiatry Psychiatr Epidemiol. 2005;40(7):529-539.
6. Kohn R, Saxena S, Levav I, Saraceno B. The treatment gap in mental health care. Bull World Health Organ. 2004;82(11):858-866.
7. Gaebel W, Riesbeck M, Wobrock T. Schizophrenia guidelines across the world: a selective review and comparison. Int Rev Psychiatry. 2011;23(4):379-387.
8. Gaebel W, Weinmann S, Sartorius N, Rutz W, McIntyre JS. Schizophrenia practice guidelines: international survey and comparison. Br J Psychiatry. 2005;187:248-255.
9. Harrington M, Lelliott P, Paton C, Okocha C, Duffet R, Sensky T. The results of a multi-centre audit of the prescribing of antipsychotic drugs for in-patients in the UK. Psychiatrist. 2002;26:414-418.
10. Rowlands P. The NICE schizophrenia guidelines: the challenge of implementation. Adv Psychiatric Treatment. 2004;10:403-412.
11. Zahiruddin O, Salleh MR. Burden of care in schizophrenia: implication of psychopathology of the illness. Malaysian J Psych. 2005;13(2): 34-40.
12. Caqueo-Urízar A, Gutiérrez-Maldonado J, Ferrer-García M, Morales AU, Fernández-Dávila P. Typology of schizophrenic symptoms and quality of life in patients and their main caregivers in northern Chile. Int J Soc Psychiatry. 2013;59(1):93-100.
13. Rudnick A. The impact of coping on the relation between symptoms and quality of life in schizophrenia. Psychiatry. 2001;64(4):304-308.
14. Daumit GL, Pratt LA, Crum RM, Powe NR, Ford DE. Characteristics of primary care visits for individuals with severe mental illness in a national sample. Gen Hosp Psychiatry. 2002;24(6):391-395.
15. Brown S, Kim M, Mitchell C, Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br J Psychiatry. 2010;196(2): 116-121.
16. Marder SR, Essock SM, Miller AL, etal. Physical health monitoring of patients with schizophrenia. Am J Psychiatry. 2004;161(8): 1334-1349.
17. Kendrick T. Cardiovascular and respiratory risk factors and symptoms among general practice patients with long-term mental illness. Br J Psychiatry. 1996;169(6):733-739.
18. Lawrence DM, Holman CD, Jablensky AV, Hobbs MS. Death rate from ischaemic heart disease in Western Australian psychiatric patients 1980-1998. Br J Psychiatry. 2003;182:31-36.
19. Osborn DP, Levy G, Nazareth I, Petersen I, Islam A, King MB. Relative risk of cardiovascular and cancer mortality in people with severe mental illness from the United Kingdom's General Practice Rsearch Database. Arch Gen Psychiatry. 2007;64(2):242-249.
20. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Time trends in schizophrenia mortality in Stockholm county, Sweden: cohort study. BMJ. 2000;321(7259):483-484.
21. Phelan M, Stradins L, Morrison S. Physical health of people with severe mental illness. BMJ. 2001;322(7284):443-444.
22. von Hausswolff-Juhlin Y, Bjartveit M, Lindström E, Jones P. Schizophrenia and physical health problems. Acta Psychiatr Scand Suppl. 2009;(438):15-21.
23. Casey DE, Haupt DW, Newcomer JW, etal. Antipsychotic-induced weight gain and metabolic abnormalities: implications for increased mortality in patients with schizophrenia. J Clin Psychiatry. 2004;65 Suppl 7:4-18.
24. Citrome L, Blonde L, Damatarca C. Metabolic issues in patients with severe mental illness. South Med J. 2005;98(7):714-720.
25. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Hum Psychopharmacol. 2008;23(3):201-209.
26. Lambert TJ, Velakoulis D, Pantelis C. Medical comorbidity in schizophrenia. Med J Aust. 2003;178 Suppl:S67-S70.
27. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry. 2004;65(2):267-272.
28. Jones PB, Barnes TR, Davies L, etal. Randomized controlled trial of the effect on Quality of Life of second-vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry. 2006;63(10):1079-1087.
29. Holt RI. Review: severe mental illness, antipsychotic drugs and the metabolic syndrome. Br J Diabetes Vascular Dis. 2006;6(5):199-204.
30. Meyer JM, Nasrallah HA. Medical Illness and Schizophrenia. Arlington, VA: American Psychiatric Publishing, Inc; 2009.
31. Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68 Suppl 4:8-13.
32. De Hert M, van Winkel R, Van Eyck D, etal. Prevalence of diabetes, metabolic syndrome and metabolic abnormalities in schizophrenia over the course of the illness: a cross-sectional study. Clin Pract Epidemiol Ment Health. 2006;2:14.
33. De Hert M, Schreurs V, Sweers K, etal. Typical and atypical antipsychotics differentially affect long-term incidence rates of the metabolic syndrome in first-episode patients with schizophrenia: a retrospective chart review. Schizophr Res. 2008;101(1-3):295-303.
34. Morrato EH, Newcomer JW, Kamat S, Baser O, Harnett J, Cuffel B. Metabolic screening after the American Diabetes Association's consensus statement on antipsychotic drugs and diabetes. Diabetes Care. 2009;32(6):1037-1042.
35. Frayne SM, Halanych JH, Miller DR, etal. Disparities in diabetes care: impact of mental illness. Arch Intern Med. 2005;165(22):2631-2638.
36. Nasrallah HA, Meyer JM, Goff DC, etal. Low rates of treatment for hypertension, dyslipidemia and diabetes in schizophrenia: data from the CATIE schizophrenia trial sample at baseline. Schizophr Res. 2006;86(1-3):15-22.
37. Osby U, Correia N, Brandt L, Ekbom A, Sparén P. Mortality and causes of death in schizophrenia in Stockholm county, Sweden. Schizophr Res. 2000;45(1-2):21-28.
38. Lin HC, Hsiao FH, Pfeiffer S, Hwang YT, Lee HC. An increased risk of stroke among young schizophrenia patients. Schizophr Res. 2008;101(1-3):234-241.
39. Glassman AH, Bigger JT Jr. Antipsychotic drugs: prolonged QTc interval, torsade de pointes, and sudden death. Am J Psychiatry. 2001; 158(11):1774-1782.
40. Appleby L, Thomas S, Ferrier N, Lewis G, Shaw J, Amos T. Sudden unexplained death in psychiatric in-patients. Br J Psychiatry. 2000;176: 405-406.
41. Copeland LA, Mortensen EM, Zeber JE, Pugh MJ, Restrepo MI, Dalack GW. Pulmonary disease among inpatient decedents: Impact of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2007;31(3):720-726.
42. Lönnroth K, Jaramillo E, Williams B, Dye C, Raviglione M. Tuberculosis: the role of risk factors and social determinants. In: Blas E, Sivasankara Kurup A, editors. Equity, Social Determinants and Public Health Programmes. Geneva: World Health Organization; 2010:219-241.
43. Winterer G. Why do patients with schizophrenia smoke? Curr Opin Psychiatry. 2010;23(2):112-119.
44. Rosenberg SD, Goodman LA, Osher FC, etal. Prevalence of HIV, hepatitis B, and hepatitis C in people with severe mental illness. Am J Public Health. 2001;91(1):31-37.
45. Barak Y, Achiron A, Mandel M, Mirecki I, Aizenberg D. Reduced cancer incidence among patients with schizophrenia. Cancer. 2005; 104(12):2817-2821.
46. Grinshpoon A, Barchana M, Ponizovsky A, etal. Cancer in schizophrenia: is the risk higher or lower? Schizophr Res. 2005;73(2-3):333-341.
47. Lawrence D, Holman CD, Jablensky AV, Threlfall TJ, Fuller SA. Excess cancer mortality in Western Australian psychiatric patients due to higher case fatality rates. Acta Psychiatr Scand. 2000;101(5):382-388.
48. DE Hert M, Correll CU, Bobes J, etal. Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care. World Psychiatry. 2011;10(1):52-77.
49. Substance Abuse and Mental Health Services Administration. Results from the 2011 National Survey on Drug use and Health: Summary of National Findings. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2012.
50. Kessler RC. The epidemiology of dual diagnosis. Biol Psychiatry. 2004;56(10):730-737.
51. Tiet QQ, Mausbach B. Treatments for patients with dual diagnosis: a review. Alcohol Clin Exp Res. 2007;31(4):513-536.
52. Goldsmith RJ, Garlapati V. Behavioral interventions for dual-diagnosis patients. Psychiatr Clin North Am. 2004;27(4):709-725.
53. Clark RE, Mueser KT. Progress in research on dual disorders. Br J Psychiatry. 2003;183:377-378.
54. Buckley PF, Miller BJ, Lehrer DS, Castle DJ. Psychiatric comorbidities and schizophrenia. Schizophr Bull. 2009;35(2):383-402.
55. Siris SG. Depression in schizophrenia: perspective in the era of "Atypical" antipsychotic agents. Am J Psychiatry. 2000;157(9): 1379-1389.
56. Cohen CI, Vahia I, Reyes P, etal. Focus on geriatric psychiatry: schizophrenia in later life: clinical symptoms and social well-being. Psychiatr Serv. 2008;59(3):232-234.
57. Eack SM, Newhill CE. Psychiatric symptoms and quality of life in schizophrenia: a meta-analysis. Schizophr Bull. 2007;33(5):1225-1237.
58. Hor K, Taylor M. Suicide and schizophrenia: a systematic review of rates and risk factors. J Psychopharmacol. 2010;24(Suppl 4):81-90.
59. Lester H, Tritter JQ, Sorohan H. Patients' and health professionals' views on primary care for people with serious mental illness: focus group study. BMJ. 2005;330(7500):1122.
60. Roberts L, Roalfe A, Wilson S, Lester H. Physical health care of patients with schizophrenia in primary care: a comparative study. Fam Pract. 2007;24(1):34-40.
61. Gierisch JM, Nieuwsma JA, Bradford DW, etal. Interventions to Improve Cardiovascular Risk Factors in People with Serious Mental Illness. Rockville, MD: Agency for Healthcare Research and Quality; 2013.
62. Moreno-Küstner B, Mayoral F, Pérez O, et al. The Malaga schizophrenia case-register (RESMA): overview of methodology and patient cohort. Int J Soc Psychiatry. 2009;55(1):5-15.
63. Moreno-Küstner B, Mayoral F, Rivas F, etal. Factors associated with use of community mental health services by schizophrenia patients using multilevel analysis. BMC Health Serv Res. 2011;11:257.
64. Moreno B, Arroyo B, Torres-González F, de Dios Luna J, Cervilla J. Social predictors of out-patient mental health contact in schizophrenia patients. Soc Psychiatry Psychiatr Epidemiol. 2007;42(6):452-456.
65. Leff J, Trieman N, Knapp M, Hallam A. The TAPS project: a report on 13 years of research, 1985-1998. Psychiatic Bull. 2000;24:165-168.
66. Devon County Council. Accomodation and Support Joint Strategic Needs Assessment for Mental Health. Exeter: Devon County Council; 2010. Available from: http://www.devon.gov.uk/jsna_mh-2.pdf. Accessed June 12, 2013.
67. Ritsner MS, Gibel A. Quality of life impairment syndrome in schizophrenia. In: Ritsner MS, Awad AG, editors. Quality of Life Impairment in Schizophrenia, Mood and Anxiety Disorders. Houten, The Netherlands: Springer; 2007.
68. McCrone P, Leese M, Thornicroft G, etal. A comparison of needs of patients with schizophrenia in five European countries: the EPSILON Study. Acta Psychiatr Scand. 2001;103(5):370-379.
69. Najim H, McCrone P. The Camberwell Assessment of Need: comparison of assessments by staff and patients in an inner-city and a semi-rural community area. Psychiatric Bull. 2005;29:13-17.
70. Thornicroft G, Tansella M, Becker T, etal; EPSILON Study Group. The personal impact of schizophrenia in Europe. Schizophr Res. 2004;69(2-3):125-132.
71. Middelboe T, Mackeprang T, Hansson L, etal. The Nordic Study on schizophrenic patients living in the community. Subjective needs and perceived help. Eur Psychiatry. 2001;16(4):207-214.
72. Hansson L, Sandlund M, Bengtsson-Tops A, etal. The relationship of needs and quality of life in persons with schizophrenia living in the community. A Nordic multi-center study. Nord J Psychiatry. 2003;57(1):5-11.
73. Gaite L, Vázquez-Barquero JL, Borra C, etal; EPSILON Study Group. Quality of life in patients with schizophrenia in five European countries: the EPSILON study. Acta Psychiatr Scand. 2002;105(4):283-292.
74. van der Plas AG, Hoek HW, van Hoeken D, Valencia E, van Hemert AM. Perceptions of quality of life and disability in homeless persons with schizophrenia and persons with schizophrenia living in non-institutional housing. Int J Soc Psychiatry. 2012;58(6):629-634.
75. Caqueo Urízar A, Lemos Giráldez S. [Quality of life and family functioning in schizophrenia patients]. Psicothema. 2008;20(4):577-582. Spanish.
76. Ochoa S, Haro JM, Autonell J, Pendàs A, Teba F, Màrquez M; NEDES Group. Met and unmet needs of schizophrenia patients in a Spanish sample. Schizophr Bull. 2002;9(2):201-210.
77. Kulhara P, Avasthi A, Grover S, etal. Needs of Indian schizophrenia patients: an exploratory study from India. Soc Psychiatry Psychiatr Epidemiol. 2010;45(8):809-818.
78. Mojtabai R, Fochtmann L, Chang SW, Kotov R, Craig TJ, Bromet E. Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first-admission study. Schizophr Bull. 2009;35(4):679-695.
79. Broadbent E, Kydd R, Sanders D, Vanderpyl J. Unmet needs and treatment seeking in high users of mental health services: role of illness perceptions. Aust N Z J Psychiatry. 2008;42(2):147-153.
80. Cleary M, Freeman A, Hunt GE, Walter G. Patient and carer perceptions of need and associations with care-giving burden in an integrated adult mental health service. Soc Psychiatry Psychiatr Epidemiol. 2006;41(3):208-214.
81. Chopra P, Herrman HE. The long-term outcomes and unmet needs of a cohort of former long-stay patients in Melbourne, Australia. Community Ment Health J. 2011;47(5):531-541.
82. Kallert TW, Leisse M, Winiecki P. Needs for care of chronic schizophrenic patients in long-term community treatment. Soc Psychiatry Psychiatr Epidemiol. 2004;39(5):386-396.
83. Killaspy H, Rambarran D, Bledin K. Mental health needs of clients of rehabilitation services: a survey in one Trust. J Mental Health. 2008;17(2):207-218.
84. Wiersma D, van den Brink R, Wolters K, etal. Individual unmet needs for care: are they sensitive as outcome criterion for the effectiveness of mental health services interventions? Soc Psychiatry Psychiatr Epidemiol. 2009;44(4):317-324.
85. Grinshpoon A, Friger M, Orev E, etal. Relative perceptions of the needs of inpatients with schizophrenia and schizoaffective disorders. Isr J Psychiatry Relat Sci. 2008;45(3):201-209.
86. Korkeila J, Heikkilä J, Hansson L, Sørgaard KW, Vahlberg T, Karlsson H. Structure of needs among persons with schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2005;40(3):233-239.
87. Werner S. Needs assessment of individuals with serious mental illness: can it help in promoting recovery? Community Ment Health J. 2012;48(5):568-573.
88. Cummings SM, Cassie KM. Perceptions of biopsychosocial services needs among older adults with severe mental illness: met and unmet needs. Health Soc Work. 2008;33(2):133-143.
89. Meesters PD, Comijs HC, Dröes RM, etal. The care needs of elderly patients with schizophrenia spectrum disorders. Am J Geriatr Psychiatry. 2013;21(2):129-137.
90. Boeing L, Murray V, Pelosi A, McCabe R, Blackwood D, Wrate R. Adolescent-onset psychosis: prevalence, needs and service provision. Br J Psychiatry. 2007;190:18-26.
91. van der Heiden W, Häfner H. The epidemiology of onset and course of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 2000;250(6): 292-303.
92. Landolt K, Rössler W, Burns T, etal; EUFEST Study Group. Unmet needs in patients with first-episode schizophrenia: a longitudinal perspective. Psychol Med. 2012;42(7):1461-1473.
93. Martínez-Martín N, Fraguas D, García-Portilla MP, etal. Self-perceived needs are related to violent behavior among schizophrenia outpatients. J Nerv Ment Dis. 2011;199(9):666-671.
94. Tidemalm D, Elofsson S, Stefansson CG, Waern M, Runeson B. Predictors of suicide in a community-based cohort of individuals with severe mental disorder. Soc Psychiatry Psychiatr Epidemiol. 2005;40(8):595-600.
95. Adewuya AO, Makanjuola RO. Subjective quality of life of Nigerian schizophrenia patients: sociodemographic and clinical correlates. Acta Psychiatr Scand. 2009;120(2):160-164.
96. Evans-Lacko S, Knapp M, McCrone P, Thornicroft G, Mojtabai R. The mental health consequences of the recession: economic hardship and employment of people with mental health problems in 27 European countries. PLoS One. 2013;8(7):e69792.
97. Harvey SB, Henderson M, Lelliott P, Hotopf M. Mental health and employment: much work still to be done. Br J Psychiatry. 2009; 194(3):201-203.
98. McGorry PD. Staging in neuropsychiatry: a heuristic model for understanding, prevention and treatment. Neurotox Res. 2010;18(3-4): 244-255.
99. Marshall M, Lewis S, Lockwood A, Drake R, Jones P, Croudace T. Association between duration of untreated psychosis and outcome in cohorts of first-episode patients: a systematic review. Arch Gen Psychiatry. 2005;62(9):975-983.
100. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry. 2005;162(10):1785-1804.
101. Mason O, Startup M, Halpin S, Schall U, Conrad A, Carr V. Risk factors for transition to first episode psychosis among individuals with 'at-risk mental states'. Schizophr Res. 2004;71(2-3):227-237.
102. Miller TJ, McGlashan TH, Rosen JL, etal. Prospective diagnosis of the initial prodrome for schizophrenia based on the Structured Interview for Prodromal Syndromes: preliminary evidence of interrater reliability and predictive validity. Am J Psychiatry. 2002;159(5):863-865.
103. Riecher-Rössler A, Gschwandtner U, Aston J, etal. The Basel early-detection-of-psychosis (FEPSY)-study-design and preliminary results. Acta Psychiatr Scand. 2007;115(2):114-125.
104. Ruhrmann S, Schultze-Lutter F, Klosterkötter J. Early detection and intervention in the initial prodromal phase of schizophrenia. Pharmacopsychiatry. 2003;36 Suppl 3:S162-S167.
105. Yung AR, Phillips LJ, Yuen HP, etal. Psychosis prediction: 12-month follow up of a high-risk ("prodromal") group. Schizophr Res. 2003;60(1):21-32.
106. International Early Psychosis Association Writing Group. International clinical practice guidelines for early psychosis. Br J Psychiatry. 2005;187:s120-s124.
107. Kahn RS, Fleischhacker WW, Boter H, etal; EUFEST study group. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet. 2008;371(9618):1085-1097.
108. Fowler D, Hodgekins J, Painter M, etal. Cognitive behaviour therapy for improving social recovery in psychosis: a report from the ISREP MRC Trial Platform Study (Improving Social Recovery in Early Psychosis). Psychol Med. 2009;39(10):1627-1636.
109. Fraser R, Berger G, Killackey E, McGorry P. Emerging psychosis in young people-Part 3-key issues for prolonged recovery. Aust Fam Physician. 2006;35(5):329-333.
110. Killackey E, Jackson HJ, McGorry PD. Vocational intervention in first-episode psychosis: individual placement and support v treatment as usual. Br J Psychiatry. 2008;193(2):114-120.
111. Eack SM, Greenwald DP, Hogarty SS, etal. Cognitive enhancement therapy for early-course schizophrenia: effects of a two-year randomized controlled trial. Psychiatr Serv. 2009;60(11):1468-1476.
112. Wykes T, Newton E, Landau S, Rice C, Thompson N, Frangou S. Cognitive remediation therapy (CRT) for young early onset patients with schizophrenia: an exploratory randomized controlled trial. Schizophr Res. 2007;94(1-3):221-230.
113. McGorry PD, Yung AR, Bechdolf A, Amminger P. Back to the future: predicting and reshaping the course of psychotic disorder. Arch Gen Psychiatry. 2008;65(1):25-27.
114. McGorry PD, Killackey E, Yung A. Early intervention in psychosis: concepts, evidence and future directions. World Psychiatry. 2008;7(3): 148-156.
115. Anthony WA. A recovery-oriented service system: setting some system level standards. Psychiatric Rehab J. 2000;24(2):159-168.
116. Pinikahana J, Hapell B, Hope J, Keks NA. Quality of life in schizophrenia: a review of the literature from 1995 to 2000. Int J Mental Health Nurs. 2002;11:103-111.
117. Aki H, Tomotake M, Kaneda Y, etal. Subjective and objective quality of life, levels of life skills, and their clinical determinants in outpatients with schizophrenia. Psychiatry Res. 2008;158(1):19-25.
118. Cavieres A, Valdebenito M. Cognitive function and quality of life in schizophrenia. Revista Chilena Neuro-Psiquiatría. 2005;43:97-108.
119. Narvaez JM, Twamley EW, McKibbin CL, Heaton RK, Patterson TL. Subjective and objective quality of life in schizophrenia. Schizophr Res. 2008;98(1-3):201-208.
120. Yamauchi K, Aki H, Tomotake M, etal. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci. 2008;62(4):404-411.
121. Falloon IR, Montero I, Sungur M, etal; OTP Collaborative Group. Implementation of evidence-based treatment for schizophrenic disorders: two-year outcome of an international field trial of optimal treatment. World Psychiatry. 2004;3(2):104-109.
122. Kreyenbuhl J, Buchanan RW, Dickerson FB, Dixon LB; Schizophrenia Patient Outcomes Research Team (PORT). The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2009. Schizophr Bull. 2010;36(1):94-103.
123. Leucht S, Tardy M, Komossa K, etal. Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet. 2012;379(9831):2063-2071.
124. Leucht S, Cipriani A, Spineli L, etal. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-962.
125. Mueser KT, Deavers F, Penn DL, Cassisi JE. Psychosocial treatments for schizophrenia. Annu Rev Clin Psychol. 2013;(9)465-497.
126. Latin America within the Local Health Systems, Pan-American Health Organization [PAHO]/World Health Organization [WHO], Venez. November 14, 1990.
127. United Nations. Principles for the protection of persons with mental illness and the improvement of mental health care, 46/119. New York: United Nations; 1991. Available from http://www.un.org/documents/ga/res/46/a46r119.htm. Accessed May 23, 2013.
128. Rosen A, Walter G, Casey D, Hocking B. Combating psychiatric stigma: an overview of contemporary initiatives. Australasian Psychiatry. 2000;8(1):19-26.
129. Thompson AH, Stuart H, Bland RC, etal; WPA. World Psychiatric Association. Attitudes about schizophrenia from the pilot site of the WPA worldwide campaign against the stigma of schizophrenia. Soc Psychiatry Psychiatr Epidemiol. 2002;37(10):475-482.
130. Health and Consumer Protection Directorate-General EC. Improving the mental health of the population: Towards a strategy on mental health for the European Union. Brussels: European Commission; 2005. Available from: http://ec.europa.eu/health/ph_determinants/life_style/mental/green_paper/mental_gp_en.pdf. Accessed May 14, 2013.
131. Kallert TW, Torres-Gonzalez F. Legislation on Coercive Mental Health Care in Europe. Legal Documents and Comparative Assessment of Twelve European Countries. Frankfurt am Main: Peter Lang; 2006.
132. Raboch J, Kalisová L, Nawka A, etal. Use of coercive measures during involuntary hospitalization: findings from ten European countries. Psychiatr Serv. 2010;61(10):1012-1017.
133. Kallert TW, Katsakou C, Adamowski T, etal. Coerced hospital admission and symptom change-a prospective observational multi-centre study. PLoS One. 2011(6):e28191.
134. Pan American Health Organization. Supporting the Implementation of Mental Health Policies in the Americas: A Human Rights Law-Based Approach. Findings, Trends and Targets for Public Health Action. Washington, DC: PAHO; 2010.
135. World Health Organization. User empowerment in mental health-a statement by the WHO Regional Office for Europe. Copenhagen: World Health Organization; 2010.
136. Demyttenaere K, Bruffaerts R, Posada-Villa J, etal; WHO World Mental Health Survey Consortium. Prevalence, severity, and unmet need for treatment of mental disorders in the World Health Organization World Mental Health Surveys. JAMA. 2004;291(21):2581-2590.
137. Priebe S, Badesconyi A, Fioritti A, etal. Reinstitutionalisation in mental health care: comparison of data on service provision from six European countries. BMJ. 2005;330(7483):123-126.
138. Torres-Gonzales F. Trastornos psiquiátricos severos: criterios de calidad (con especial énfasis en el tratamiento asertivo comunitario). [Severe Psychiatric Disorders: quality criteria (with special emphasis in assertive community treatment)] Revista GPU. 2013;9(1):75-80. Spanish.
139. Patel V, Maj M, Flisher AJ, De Silva MJ, Koschorke M, Prince M; WPA Zonal and Member Society Representatives. Reducing the treatment gap for mental disorders: a WPA survey. World Psychiatry. 2010;9(3):169-176.
140. Quinlivan R, Hough R, Crowell A, Beach C, Hofstetter R, Kenworthy K. Service utilization and costs of care for severely mentally ill clients in an intensive case management program. Psychiatr Serv. 1995;46(4): 365-371.
141. Scott JE, Dixon LB. Assertive community treatment and case management for schizophrenia. Schizophr Bull. 1995;21(4):657-668.
142. Meyer PS, Morrissey JP. A comparison of assertive community treatment and intensive case management for patients in rural areas. Psychiatr Serv. 2007;58(1):121-127.
143. Coldwell CM, Bender WS. The effectiveness of assertive community treatment for homeless populations with severe mental illness: a meta-analysis. Am J Psychiatry. 2007;164(3):393-399.
144. Nelson G, Aubry T, Lafrance A. A review of the literature on the effectiveness of housing and support, assertive community treatment, and intensive case management interventions for persons with mental illness who have been homeless. Am J Orthopsychiatry. 2007;77(3): 350-361.
145. Endacott R, Eliott S, Chaboyer W. An integrative review and meta-synthesis of the scope and impact of intensive care liaison and outreach services. J Clin Nurs. 2009;18(23):3225-3236.
146. Dieterich M, Irving CB, Park B, Marshall M. Intensive case management for severe mental illness. Cochrane Database Syst Rev. 2010;(10):CD007906.
147. Pitt V, Lowe D, Hill S, etal. Consumer-providers of care for adult clients of statutory mental health services. Cochrane Database Syst Rev. 2013;3:CD004807.
148. Shean GD. Empirically Based Psychosocial Therapies for Schizophrenia: The Disconnection between Science and Practice. Schizophr Res Treatment. 2013;2013:792769.
149. Archer J, Bower P, Gilbody S, etal. Collaborative care for depression and anxiety problems. Cochrane Database Syst Rev. 2012;10: CD006525.
150. Lee S, Keating C, de Castella A, Kulharni J. Fitting together the pieces: collaborative care models for adulst with severe and persistent mental illness. Camberra: National Advisory Council on Mental Health; 2010. Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/0ABBFD239D790377CA257BF0001C6CBC/$File/colsev.pdf. Accessed June 24, 2013.
151. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ. Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry. 2013;70(9):913-920.
152. Agius M, Goh C, Ulhaq S, McGorry P. The staging model in schizophrenia, and its clinical implications. Psychiatr Danub. 2010;22(2):211-220.
153. Ruiz-Iriondo M, Salaberria K, Echeburúa E. Schizophrenia: analysis and psychological treatment according to the clinical staging. Actas Esp Psiquiatr. 2013;41(1):52-59.